AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21297190 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic (ATM; 65% VO₂peak)
Number of subjects: 30
Study 21297190 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-intensity resistance (RTL; 50% VO₂peak)
Number of subjects: 30
Study 18768369 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg/day for 5 years)
Number of subjects: 227
Study 18768369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 18768369 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 227
Study 16361368 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytoestrogens (resveratrol and genistein) and selective estrogen receptor-alpha agonist (PPT)
Number of subjects: 0
Study 16361368 — intervention group
Group type: EXPERIMENTAL
Intervention: PPT and genistein
Number of subjects: 0
Study 16361368 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytoestrogens and PPT
Number of subjects: 0
Study 16361368 — intervention group
Group type: COMPARATOR
Intervention: 17beta‐E2
Number of subjects: 0
Study 15273454 — intervention group
Group type: EXPERIMENTAL
Intervention: Backup pacing (AAI at 30 beats per minute)
Number of subjects: 32
Study 15273454 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrioventricular interval (AVI) of 30 ms (DDD30)
Number of subjects: 32
Study 15273454 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized AVI (DDDop)
Number of subjects: 32
Study 15273454 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-of-life (QOL) testing
Number of subjects: 32
Study 11456430 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 750
Study 9226602 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexually explicit video before sleep
Number of subjects: 12
Study 9226602 — intervention group
Group type: COMPARATOR
Intervention: Dysphoric arousal video before sleep
Number of subjects: 12
Study 9226602 — intervention group
Group type: COMPARATOR
Intervention: Lecture (neutral) video before sleep
Number of subjects: 12
Study 8289616 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair-climbing (STAIR)
Number of subjects: 23
Study 8289616 — intervention group
Group type: COMPARATOR
Intervention: Run training (RUN)
Number of subjects: 23
Study 8289616 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (STAIR and RUN)
Number of subjects: 23
Study 3542775 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (150 micrograms)
Number of subjects: 12
Study 3542775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31778310 — intervention group
Group type: EXPERIMENTAL
Intervention: Gravity-induced blood flow restriction (BFR) aerobic exercise (AE)
Number of subjects: 13
Study 31778310 — intervention group
Group type: COMPARATOR
Intervention: Work rate‐matched non‐BFR aerobic exercise (AE)
Number of subjects: 13
Study 30067289 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemetric gas-sensing capsule (1.25-40 g inulin)
Number of subjects: 12
Study 30067289 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemetric gas-sensing capsule (20 or 40 g glucose)
Number of subjects: 12
Study 30067289 — intervention group
Group type: COMPARATOR
Intervention: Breath test (standard protocols)
Number of subjects: 12
Study 27998215 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (3 telephone-based sessions over 1 month)
Number of subjects: 164
Study 25948727 — intervention group
Group type: EXPERIMENTAL
Intervention: IV bolus injection of 2.0 mg/kg cyclosporine
Number of subjects: 127
Study 25948727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 23418886 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based guided self-help course (6 weekly lessons with weekly support from a coach)
Number of subjects: 200
Study 23418886 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (no additional treatment)
Number of subjects: 200
Study 20635617 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative testing
Number of subjects: 2
Study 20635617 — intervention group
Group type: COMPARATOR
Intervention: Individual testing
Number of subjects: 2
Study 18254985 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrot juice (330 ml per day for 2 weeks)
Number of subjects: 22
Study 18254985 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato juice (330 ml per day for 2 weeks)
Number of subjects: 22
Study 18254985 — intervention group
Group type: COMPARATOR
Intervention: Carrot juice and Tomato juice
Number of subjects: 22
Study 16175532 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse incision (n = 32)
Number of subjects: 69
Study 16175532 — intervention group
Group type: COMPARATOR
Intervention: Vertical incision (n = 37)
Number of subjects: 69
Study 12843036 — intervention group
Group type: EXPERIMENTAL
Intervention: ETB-positive S. aureus strains
Number of subjects: 0
Study 12843036 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of staphylococcal plasmid encoding multiple antibiotic resistance traits
Number of subjects: 0
Study 12843036 — intervention group
Group type: EXPERIMENTAL
Intervention: Staphylococcal nasal carriage
Number of subjects: 0
Study 12843036 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonal type of S. aureus
Number of subjects: 0
Study 10374223 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial gestagen treatment (5 mg medroxyprogesterone acetate, twice daily, for 10 days)
Number of subjects: 86
Study 10374223 — intervention group
Group type: COMPARATOR
Intervention: Continuous combined hormone replacement therapy without initial gestagen treatment
Number of subjects: 86
Study 10374223 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial gestagen treatment
Number of subjects: 86
Study 10374223 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative progesterone challenge test
Number of subjects: 86
Study 10374223 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive progesterone challenge test
Number of subjects: 86
Study 8708877 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (6-week group treatment providing nutritional education and management strategies)
Number of subjects: 9
Study 8708877 — intervention group
Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 9
Study 8708877 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 9
Study 2065411 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 50 micrograms.kg-1 infused over 30 sec (Group 1)
Number of subjects: 80
Study 2065411 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 25 micrograms.kg-1 infused (Group 2)
Number of subjects: 80
Study 2065411 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 12.5 micrograms.kg-1 infused (Group 3)
Number of subjects: 80
Study 2065411 — intervention group
Group type: COMPARATOR
Intervention: No alfentanil administered (Group 4)
Number of subjects: 80
Study 6558011 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff support program (9 weeks, insight-oriented approach with structured exercises)
Number of subjects: 0
Study 6558011 — intervention group
Group type: COMPARATOR
Intervention: Pre-program levels of stress and job satisfaction
Number of subjects: 0
Study 6558011 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-program levels of stress
Number of subjects: 0
Study 6558011 — intervention group
Group type: EXPERIMENTAL
Intervention: Job satisfaction post-program
Number of subjects: 0
Study 6558011 — intervention group
Group type: EXPERIMENTAL
Intervention: Turnover among nursing staff on hospice unit
Number of subjects: 0
Study 31982887 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of monochromatic 308-nm excimer light (MEL) and topical calcipotriol
Number of subjects: 18
Study 31982887 — intervention group
Group type: COMPARATOR
Intervention: Topical calcipotriol alone
Number of subjects: 18
Study 31982887 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MEL and topical calcipotriol
Number of subjects: 18
Study 30786757 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with repaired cleft palate
Number of subjects: 76
Study 30786757 — intervention group
Group type: COMPARATOR
Intervention: Participants without cleft palate
Number of subjects: 76
Study 29960800 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT and Tdap co-administered at Month 0 (Co-ad group)
Number of subjects: 660
Study 29960800 — intervention group
Group type: COMPARATOR
Intervention: MenACWY-TT at Month 0 and Tdap at Month 1 (ACWY_Tdap group)
Number of subjects: 660
Study 29960800 — intervention group
Group type: COMPARATOR
Intervention: Tdap at Month 0 and MenACWY-TT at Month 1 (Tdap_ACWY group)
Number of subjects: 660
Study 29960800 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 660
Study 29960800 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT and Tdap co-administered
Number of subjects: 660
Study 27630949 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine gluconate mouthwash
Number of subjects: 45
Study 27630949 — intervention group
Group type: EXPERIMENTAL
Intervention: Arimedadi oil mouthwash
Number of subjects: 45
Study 25212745 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 1358
Study 25212745 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (5/5 stratum)
Number of subjects: 1358
Study 25212745 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5/5 stratum)
Number of subjects: 1358
Study 25212745 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (5/x+x/x stratum)
Number of subjects: 1358
Study 25212745 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5/x+x/x stratum)
Number of subjects: 1358
Study 22633362 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical mitomycin C (MMC) 40 mg/40 ml, three instillations per week for 2 weeks (group 2)
Number of subjects: 54
Study 22633362 — intervention group
Group type: COMPARATOR
Intervention: Intravesical mitomycin C (MMC) 40 mg/40 ml, one instillation per week for 6 weeks (group 1)
Number of subjects: 54
Study 20211945 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 691
Study 20211945 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 691
Study 17164834 — intervention group
Group type: EXPERIMENTAL
Intervention: In-center daily HD (1.5-2.75 h, 6 days/week)
Number of subjects: 250
Study 17164834 — intervention group
Group type: EXPERIMENTAL
Intervention: Home nocturnal HD (≥ 6 h, 6 nights/week)
Number of subjects: 250
Study 17164834 — intervention group
Group type: COMPARATOR
Intervention: In-center daily HD
Number of subjects: 250
Study 17164834 — intervention group
Group type: COMPARATOR
Intervention: Home nocturnal HD
Number of subjects: 250
Study 15886432 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced respiration
Number of subjects: 0
Study 12050241 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) at a dose of 0.005-0.010 mg/kg.d for 6 months
Number of subjects: 115
Study 12050241 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 115
Study 12050241 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH)
Number of subjects: 115
Study 12050241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 10760843 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral solution (5 mg)
Number of subjects: 14
Study 10760843 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tablet formulation (5 mg)
Number of subjects: 14
Study 10760843 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion (5 mg)
Number of subjects: 14
Study 8672197 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual therapy
Number of subjects: 42
Study 8672197 — intervention group
Group type: COMPARATOR
Intervention: Group therapy
Number of subjects: 42
Study 2147698 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate ointment 0.05%
Number of subjects: 0
Study 2147698 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 343032 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of ibuprofen
Number of subjects: 510
Study 343032 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg of ibuprofen
Number of subjects: 510
Study 343032 — intervention group
Group type: COMPARATOR
Intervention: 650 mg of aspirin
Number of subjects: 510
Study 343032 — intervention group
Group type: COMPARATOR
Intervention: 65 mg of propoxyphene HCl
Number of subjects: 510
Study 343032 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 510
Study 31941553 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing habitual correction (cc)
Number of subjects: 30
Study 31941553 — intervention group
Group type: COMPARATOR
Intervention: Not wearing habitual correction (sc)
Number of subjects: 30
Study 31941553 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing habitual correction (cc) for IED detection
Number of subjects: 30
Study 31941553 — intervention group
Group type: COMPARATOR
Intervention: Not wearing habitual correction (sc) for IED detection
Number of subjects: 30
Study 31464100 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional care as per the algorithm (oral supplements, nasogastric feeds, and/or parenteral nutrition)
Number of subjects: 50
Study 31464100 — intervention group
Group type: COMPARATOR
Intervention: Institutional standard of care
Number of subjects: 50
Study 31464100 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional care as per the algorithm
Number of subjects: 50
Study 31304457 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Counseling (TC)
Number of subjects: 669
Study 31304457 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 669
Study 27525497 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment (supination sugar-tong splinting)
Number of subjects: 157
Study 27525497 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (DRUJ transfixation)
Number of subjects: 157
Study 27525497 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (arthroscopic triangular fibrocartilage complex repair)
Number of subjects: 157
Study 24887458 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1)
Number of subjects: 137
Study 24887458 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab plus docetaxel (HT)
Number of subjects: 137
Study 22030444 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 24
Study 22030444 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 24
Study 19882460 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in research
Number of subjects: 0
Study 19882460 — intervention group
Group type: COMPARATOR
Intervention: Drug users not participating in the research
Number of subjects: 0
Study 17456522 — intervention group
Group type: EXPERIMENTAL
Intervention: Health services intervention to train health personnel in TB testing and isoniazid prophylaxis
Number of subjects: 0
Study 17456522 — intervention group
Group type: COMPARATOR
Intervention: Control group (clinics not receiving the intervention)
Number of subjects: 0
Study 15988586 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mAs (Group A)
Number of subjects: 75
Study 15988586 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mAs (Group B)
Number of subjects: 75
Study 15988586 — intervention group
Group type: COMPARATOR
Intervention: 130 mAs (Group C)
Number of subjects: 75
Study 12213743 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous triiodothyronine administration (bolus followed by 6 hours infusion)
Number of subjects: 60
Study 12213743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10452769 — intervention group
Group type: EXPERIMENTAL
Intervention: Active air cleaners
Number of subjects: 20
Study 10452769 — intervention group
Group type: COMPARATOR
Intervention: Sham air cleaners
Number of subjects: 20
Study 8591798 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose L-dopa/benserazide (300/75 mg)
Number of subjects: 29
Study 8591798 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 29
Study 2677988 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy for bone metastasis
Number of subjects: 131
Study 2677988 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy for lung cancer patients with bone metastasis
Number of subjects: 131
Study 934556 — intervention group
Group type: EXPERIMENTAL
Intervention: T-tube suction drainage alone
Number of subjects: 451
Study 934556 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics alone
Number of subjects: 451
Study 934556 — intervention group
Group type: EXPERIMENTAL
Intervention: T-tube suction drainage and prophylactic antibiotics in combination
Number of subjects: 451
Study 934556 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 451
Study 31739177 — intervention group
Group type: EXPERIMENTAL
Intervention: TruvadaⓇ-PrEP (tenofovir and emtricitabine)
Number of subjects: 544
Study 31739177 — intervention group
Group type: COMPARATOR
Intervention: Chemsex engagement
Number of subjects: 544
Study 31739177 — intervention group
Group type: COMPARATOR
Intervention: <7/7 intended doses (ID)
Number of subjects: 544
Study 27908896 — intervention group
Group type: EXPERIMENTAL
Intervention: Written patient-targeted feedback
Number of subjects: 375
Study 27908896 — intervention group
Group type: COMPARATOR
Intervention: No written patient feedback (control group)
Number of subjects: 375
Study 26957979 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 100
Study 26957979 — intervention group
Group type: COMPARATOR
Intervention: Resistance exercise training
Number of subjects: 100
Study 24365779 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 27
Study 24365779 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Training (PT)
Number of subjects: 27
Study 24365779 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 27
Study 21480321 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 50
Study 21480321 — intervention group
Group type: COMPARATOR
Intervention: Entecavir
Number of subjects: 50
Study 19622782 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rosiglitazone (4 mg/day)
Number of subjects: 0
Study 19622782 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rosiglitazone (8 mg/day)
Number of subjects: 0
Study 19622782 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose metformin (2,000 mg/day)
Number of subjects: 0
Study 19622782 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose combination rosiglitazone-metformin therapy (4 mg + 1,000 mg/day)
Number of subjects: 0
Study 19622782 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rosiglitazone-metformin combination therapy (8 mg + 2,000 mg/day)
Number of subjects: 0
Study 19622782 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (TZDs)
Number of subjects: 0
Study 15672555 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 0.5 mg
Number of subjects: 22
Study 15672555 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 1.0 mg
Number of subjects: 22
Study 10915412 — intervention group
Group type: EXPERIMENTAL
Intervention: DCLHb (10% diaspirin cross-linked hemoglobin)
Number of subjects: 139
Study 10915412 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 139
Study 7488475 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural morphine 2 mg (group M)
Number of subjects: 24
Study 7488475 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine 10 ml (group L)
Number of subjects: 24
Study 7488475 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of morphine 2 mg and 2% lignocaine 10 ml (group ML)
Number of subjects: 24
Study 2048820 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (30 mg)
Number of subjects: 16
Study 2048820 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 16
Study 2048820 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide (2 mg)
Number of subjects: 16
Study 6167346 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum, vinblastine, and bleomycin
Number of subjects: 137
Study 6167346 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dosage of vinblastine (0.3 mg/kg)
Number of subjects: 137
Study 6167346 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance vinblastine
Number of subjects: 137
Study 6167346 — intervention group
Group type: EXPERIMENTAL
Intervention: Four courses of remission induction therapy
Number of subjects: 137
Study 6167346 — intervention group
Group type: EXPERIMENTAL
Intervention: High cure rate in Stage B disease
Number of subjects: 137
Study 30447984 — intervention group
Group type: EXPERIMENTAL
Intervention: INFIX
Number of subjects: 10
Study 30447984 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic Bridge
Number of subjects: 10
Study 30447984 — intervention group
Group type: COMPARATOR
Intervention: APEF (anterior pelvic external fixation)
Number of subjects: 10
Study 27488572 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management intervention
Number of subjects: 29
Study 27488572 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 29
Study 26375942 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg once daily for 2 weeks followed by raltegravir 400 mg twice daily for 5 days
Number of subjects: 24
Study 26375942 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir 400 mg twice daily for 5 days
Number of subjects: 24
Study 24820225 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency TENS (10 Hz)
Number of subjects: 29
Study 24820225 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency TENS (100 Hz)
Number of subjects: 29
Study 24820225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 22650964 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of vitamin B12 (1 mg/day in weeks 1-8 and 1 mg/week in weeks 9-52)
Number of subjects: 320
Study 22650964 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular administration of vitamin B12 (1 mg on alternate days in weeks 1 and 2, 1 mg/week in weeks 3-8, and 1 mg/month in weeks 9-52)
Number of subjects: 320